Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Get insights into the latest critical issues in drug pricing worldwide from Pharma Intelligence.
17 Total results for product and free and sample content found
Datamonitor Healthcare
02 Jul 2021
One hundred billion dollars. That is the combined revenue of the top 10 pharmaceuticals in 2020, marking the first year in which this threshold has been crossed.
Topic Drug Review Drug Pricing
Pink Sheet, Scrip
25 May 2021
Tap into expert coverage of the complex world of drug pricing with insights from analysts at Scrip and Pink Sheet. This eBook includes vital information about issues affecting drug pricing for the US, EU, and other global markets, including patient access, regulatory issues, commercial challenges, value-based pricing, and more.
Topic Drug Pricing
Biomedtracker
03 Mar 2021
This is both an updated study of clinical drug development success rates from our 2016 report, and an expansion into the drivers of success with the addition of machine learning modeling to analyze the predictive factors contributing to drug development.
Topic Clinical Trials Drug Development Landscape Drug Pricing
Datamonitor Healthcare, Pink Sheet, Scrip, Me...
28 Jan 2021
Listen to the Pharma Intelligence podcasts on Spotify, Apple Podcasts, Soundcloud and Alexa
Topic Coronavirus Manufacturing Market Intelligence Clinical Trials Blog Clinical Trials Drug Pricing
Pink Sheet
By Cathy Kelly 18 Nov 2020
Regardless of the outcomes of the US elections, drug pricing is likely to take a back seat to COVID as policy focus. But the pandemic does offer pharma an opportunity for partnerships with payers on health outcomes. Commonwealth Fund’s Liz Fowler, South Capitol’s John O’Brien and ICER’s Steve Pearson discuss where drug pricing stands in public opinion, whether policies embraced by President Trump will have staying power, and the conditions needed in the policy environment for major change.
Pink Sheet
By Cathy Kelly 18 Nov 2020
A Biden Administration with near-term priorities other than drug pricing and a Republican-controlled Senate dedicated to blocking any legislation that would enact government price controls is a relatively positive outcome for industry
Topic US Election 2020 Drug Pricing
Pink Sheet
By Cathy Kelly 17 Nov 2020
Germany uses government facilitated price negotiations between publicly funded insurers and manufacturers that are based on an independent assessment of how much added value a drug provides.
Topic US Election 2020 Drug Pricing
Pink Sheet
By Nielsen Hobbs 02 Oct 2020
Trump and Biden trade barbs in debate that included a suggestion by the president that coronavirus vaccine development delays are political and saw Biden questioned on whether he was contributing to vaccine hesitancy.
No Records Found
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Client Services
Contact us for product technical and account support.
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
